You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lymphocytes

Showing 26 - 50 of 6,538
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Melanoma Trial in New Haven (Tumor Infiltrating Lymphocytes, Nivolumab and Ipilimumab)

Terminated
  • Metastatic Melanoma
  • Tumor Infiltrating Lymphocytes
  • Nivolumab and Ipilimumab
  • New Haven, Connecticut
    Yale New Haven Hospital
Jul 20, 2022

Gastric Cancer, Colon Cancer, Rectal Cancer Trial in Wuhu (CEA-targeted CAR-T cells)

Recruiting
  • Gastric Cancer
  • +7 more
  • CEA-targeted CAR-T cells
  • Wuhu, Anhui, China
    The First Affiliated Hospital of Wannan Medical College
Nov 9, 2023

Breast Tumors Trial in Guangzhou (procedure, drug, biological)

Recruiting
  • Breast Neoplasms
  • Sentinel Lymph Node Biopsy (SLNB)
  • +7 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Jul 31, 2023

Metastatic Melanoma Trial in New York (Lifileucel (LN-144))

Recruiting
  • Metastatic Melanoma
  • Lifileucel (LN-144)
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Jan 23, 2023

Biliary Tract Cancer, Cholangiocarcinoma, Biliary Tract Tumors Trial in Pittsburgh (Tumor Infiltrating Lymphocytes (TIL))

Recruiting
  • Biliary Tract Cancer
  • +2 more
  • Tumor Infiltrating Lymphocytes (TIL)
  • Pittsburgh, Pennsylvania
    Allyson Welsch
Jul 21, 2022

NSCLC Trial in Yichang (Sindillimab)

Completed
  • Non-small Cell Lung Cancer
  • Yichang, Hubei, China
    Department of Medical Oncology, Central Hospital of Yichang City
Mar 29, 2023

Metastatic Triple Negative Breast Cancer Trial in New Haven (Tumor infiltrating lymphocytes (TIL) LN-145)

Recruiting
  • Metastatic Triple Negative Breast Cancer
  • Tumor infiltrating lymphocytes (TIL) LN-145
  • New Haven, Connecticut
    Yale School of Medicine
Jul 20, 2022

Acute Myeloid Leukemia Trial in Kunming (Anti-CLL1 CART cells)

Recruiting
  • Acute Myeloid Leukemia
  • Anti-CLL1 CART cells
  • Kunming, Yunnan, China
    No.212 Daguan Road, Xishan District
Nov 23, 2022

Multiple Myeloma Trial in Houston (TAA-specific CTLs, TAA-specific CTLs- fixed dose)

Recruiting
  • Multiple Myeloma
  • TAA-specific CTLs
  • TAA-specific CTLs- fixed dose
  • Houston, Texas
    Houston Methodist Hospital
Nov 11, 2022

CD4+T Lymphocytes in Primary Nephrotic Syndrome With Infection

Recruiting
  • Nephrotic Syndrome
  • +2 more
  • The study is an observational study without intervention
  • Zhuhai, Guangdong, China
    the fifth affiliated hospital of SUN YAT-SEN university
Nov 20, 2022

Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer Trial run by the National Cancer Institute

Recruiting
  • Metastatic Colorectal Cancer
  • +4 more
  • Young TIL
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 25, 2023

Solid Tumor Trial in Washington (Tumor-associated antigen-specific T cell (TAA-T))

Recruiting
  • Solid Tumor
  • Tumor-associated antigen-specific T cell (TAA-T)
  • Washington, District of Columbia
    Children's National Hospital
Oct 24, 2022

Advanced Solid Tumor Trial (HS-IT101)

Not yet recruiting
  • Advanced Solid Tumor
  • HS-IT101
  • (no location specified)
Sep 12, 2022

Pleural Mesothelioma Trial in Toronto (Cyclophosphamide, Fludarabine, Autologous tumor infiltrating lymphocytes (TILs))

Completed
  • Pleural Mesothelioma
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jan 8, 2023

Tumor Infiltrating Lymphocytes, Safety, Advanced Solid Tumor Trial in Beijing (TIL therapy)

Recruiting
  • Tumor Infiltrating Lymphocytes
  • +5 more
  • TIL therapy
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Dec 19, 2022

Gastric Cancer, Colorectal Cancer, Pancreatic Cancer Trial in Pittsburgh (Tumor Infiltrating Lymphocytes (TIL), Fludarabine +

Recruiting
  • Gastric Cancer
  • +9 more
  • Tumor Infiltrating Lymphocytes (TIL)
  • Fludarabine + Cyclophosphamide combination
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Jul 21, 2022

Solid Tumor Trial (LM103)

Not yet recruiting
  • Solid Tumor
  • LM103
  • (no location specified)
Jul 25, 2023

Solid Tumors Trial in Washington (Tumor associated antigen lymphocytes (TAA-CTL))

Active, not recruiting
  • Solid Tumors
  • Tumor associated antigen lymphocytes (TAA-CTL)
  • Washington, District of Columbia
    Children's National Medical Center
Jun 1, 2022

Advanced Breast Cancer, Advanced Lung Cancer Trial (Tumor-infiltrating lymphocytes, IL-2)

Not yet recruiting
  • Advanced Breast Cancer
  • Advanced Lung Cancer
  • Tumor-infiltrating lymphocytes
  • IL-2
  • (no location specified)
Oct 26, 2023

Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor, Symptomatic COVID-19 Infection Laboratory-Confirmed Trial in

Recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +2 more
  • SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes
  • Houston, Texas
    M D Anderson Cancer Center
Jul 13, 2022

Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7 Trial in

Completed
Has Results
  • Stage III Cutaneous Melanoma AJCC v7
  • +5 more
  • Aldesleukin
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 17, 2022

Uveal Melanoma, Melanoma, Metastatic Uveal Melanoma Trial in Harrison, New York (Lifileucel (LN-144))

Recruiting
  • Uveal Melanoma
  • +3 more
  • Lifileucel (LN-144)
  • Harrison, New York
  • +1 more
Nov 8, 2022

Solid Tumor Trial (LM103)

Not yet recruiting
  • Solid Tumor
  • LM103
  • (no location specified)
Jul 25, 2023

Different Dietary Protocols on Determinants of Health in

Recruiting
  • Asymptomatic Condition
  • food choices
  • Izola, Slovenia
    University of Primorska Faculty of Health Sciences
Sep 1, 2022

Non Small Cell Lung Cancer, Stage IV NSCLC, Recurrent Non Small Cell Lung Cancer Trial in Tampa (biological, drug, other)

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Tumor-infiltrating Lymphocytes (TIL)
  • +5 more
  • Tampa, Florida
    Moffitt Cancer Center
Dec 28, 2022